Meeting
2012 ASCO Annual Meeting
The PERSEPHONE trial: Duration of trastuzumab with chemotherapy in women with HER2-positive early breast cancer.
Authors
Helena Margaret Earl
Department of Oncology, University of Cambridge, and NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
Helena Margaret Earl , David A. Cameron , David Miles , Andrew M. Wardley , Emma Ogburn , A-L Vallier , Shrushma Loi , Helen B Higgins , Louise Hiller , Janet A Dunn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Clinical Trial Registration Number
52968807
Citation
J Clin Oncol 30, 2012 (suppl; abstr TPS660)
DOI
10.1200/jco.2012.30.15_suppl.tps660
Abstract #
TPS660
Poster Bd #
16G
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Predictor of trastuzumab-induced cardiotoxicity in breast cancer (BC) patients: HER2/neu 655 polymorphisms, biochemical and clinical features.
First Author: Isabel Blancas
Poster
2016 ASCO Annual Meeting
Improved outcomes in stage I HER2 positive breast cancer patients treated with trastuzumab and chemotherapy.
First Author: Shruti Rakesh Tiwari
Poster
2014 ASCO Annual Meeting
PERSEPHONE: Duration of trastuzumab with chemotherapy in patients with HER2-positive early breast cancer—Six versus twelve months.
First Author: Helena Margaret Earl
Poster
2013 ASCO Annual Meeting
PERSEPHONE: Duration of trastuzumab with chemotherapy in women with HER2-positive early breast cancer—Six versus twelve months.
First Author: Helena Margaret Earl